S-1/A: PMGC Holdings Files S-1/A for Resale of 5M Shares, Details Acquisitions

PMGC Holdings Inc. filed an S-1/A registration statement for the resale of up to 5,000,000 shares of common stock by selling security holders, while detailing recent acquisitions and an equity line of credit.

Summary

• PMGC Holdings Inc. is registering 5,000,000 shares of common stock for resale by certain selling security holders, including Streeterville Capital, LLC.
• The company will not receive any proceeds from the sale of these 5,000,000 shares by selling shareholders, but may receive up to $20,000,000 from an equity purchase facility with Streeterville.
• PMGC Holdings operates a diverse portfolio of four wholly-owned subsidiaries: Northstrive Biosciences Inc. (biopharmaceutical), PMGC Capital LLC (multi-strategy investment), Pacific Sun Packaging, Inc. (specialty packaging), and AGA Precision Systems LLC (CNC machine shop).
• On October 26, 2025, AGA Precision Systems LLC acquired assets from Indarg Engineering, Inc. for $548,000, including $350,000 to satisfy an SBA loan, $28,000 cash, and a $170,000 promissory note.
• On July 18, 2025, PMGC acquired 100% of AGA Precision Systems LLC for $650,000 in cash.
• On July 7, 2025, PMGC acquired 100% of Pacific Sun Packaging Inc. for $1,148,000 in cash and a contingent earnout of up to $250,000 based on 2025 revenue targets.
• The company completed the divestiture of its Elevai Skincare Inc. business on January 16, 2025, to focus on larger markets and biotechnology assets.
• Northstrive Biosciences' lead asset, EL-22, an engineered probiotic for muscle preservation during weight loss (including GLP-1 treatments), completed a Phase 1 clinical trial in South Korea showing promising safety and tolerability.
• PMGC Holdings reported a net loss from continuing operations of $4,776,319 for the nine months ended September 30, 2025, compared to $2,298,885 for the same period in 2024.
• Revenue from continuing operations for the nine months ended September 30, 2025, was $285,948, up from $nil in the prior year, primarily from newly acquired subsidiaries Pacific Sun ($179,292) and AGA ($106,656).
• Gross profit for the nine months ended September 30, 2025, was $78,030, with an overall gross margin of 27% (45% for IT packaging when normalizing for fair value adjustment to inventory).
• Operating expenses significantly increased to $4,492,173 for the nine months ended September 30, 2025, from $1,981,831 in the prior year, driven by higher consulting fees, office & administration, professional fees, and repairs & maintenance.
• The company had cash of $7,700,562 as of September 30, 2025, an increase from $3,984,453 at December 31, 2024, due to financing activities.
• Net working capital was $4,310,939 as of September 30, 2025, compared to $4,251,867 at December 31, 2024.
• The company effected a 1:3.5 reverse stock split on September 2, 2025, following a 1:7 split on March 10, 2025, and a 1:200 split on November 27, 2024 (combined 1-for-4,900 reverse split).
• Voting control is concentrated with Northstrive Companies Inc. and GB Capital Ltd. (wholly owned by Chairman Braeden Lichti and CEO Graydon Bensler, respectively), holding approximately 81.11% of the company's voting capital stock.
• The company adopted the 2025 Equity Incentive Plan on September 15, 2025, reserving 25% of issued and outstanding common stock, with an evergreen provision for annual increases.
• The company increased its authorized common stock from 81,632,654 to 2,000,000,000 shares on September 15, 2025.

Sentiment

Score: 3

Explanation: The company is undergoing a significant strategic shift with new acquisitions and a focus on biotechnology, which presents long-term potential. However, current financial performance shows increasing losses and cash burn, coupled with a 'going concern' warning. The reliance on related-party consulting and the dilutive nature of recent financing activities also weigh negatively on the short-term outlook and investor confidence, despite the capital raised.

Positives

• Successful divestiture of the skincare business allows for greater focus and resources on biotechnology and larger markets.
• Acquisition of Pacific Sun Packaging Inc. and AGA Precision Systems LLC diversifies the company's portfolio into specialty packaging and high-tolerance CNC machining, generating new revenue streams.
• Northstrive Biosciences' lead asset, EL-22, completed a Phase 1 clinical trial with promising safety and tolerability results, advancing its biotechnology pipeline.
• The company secured an equity line of credit of up to $20,000,000 with Streeterville Capital, LLC, providing a potential source of future funding.
• Cash balance increased significantly to $7,700,562 as of September 30, 2025, from $3,984,453 at December 31, 2024, primarily due to financing activities.
• New revenue streams from acquired subsidiaries contributed $285,948 for the nine months ended September 30, 2025, compared to nil in the prior year.
• The company has a comprehensive intellectual property portfolio, including patents and patent applications for its biotechnology assets.

Negatives

• The company has a history of net losses and its financial statements are prepared on a going-concern basis, indicating substantial doubt about its ability to continue operations.
• Net loss from continuing operations significantly increased to $4,776,319 for the nine months ended September 30, 2025, from $2,298,885 in the prior year.
• Operating expenses rose substantially to $4,492,173 for the nine months ended September 30, 2025, from $1,981,831 in the prior year, outpacing revenue growth.
• The company used $4,183,881 in cash for operating activities during the nine months ended September 30, 2025, indicating continued cash burn.
• Voting control is highly concentrated (81.11%) with entities owned by the Chairman and CEO, limiting influence for other shareholders.
• The equity line of credit with Streeterville Capital, LLC, and the exercise of warrants, will result in significant dilution for existing common stockholders.
• The company's obligations under the Pre-Paid Purchases and other Transaction Documents are secured by the assets and equity interests of its subsidiaries AGA and Pacific Sun, increasing financial risk.
• Significant related party transactions, including substantial consulting fees and bonus payments to entities controlled by the CEO and Chairman, raise corporate governance concerns.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses, limited revenue, and limited working capital.
• Inability to secure sufficient funds through future offerings or debt financing to sustain operations, potentially leading to delays, reductions, or elimination of planned activities, including R&D and acquisitions.
• Failure to achieve or maintain profitability in the future, as the company has incurred net losses since inception.
• Inability to effectively manage future growth or evaluate future prospects, especially with expansion into new product categories and global markets.
• Loss of key personnel or inability to attract and retain qualified personnel, particularly in finance, acquisitions, clinical development, and regulatory affairs, could impair business execution.
• Acquisition strategy exposes the company to risks such as difficulties in integrating operations, unanticipated costs, liabilities, and potential disputes.
• Failure to realize anticipated benefits from acquisitions, such as increased revenues or operational efficiencies, could adversely affect growth and financial performance.
• Diversification strategy may increase exposure to risks across multiple industries, requiring substantial resources and expertise to manage.
• Inability to finance future acquisitions or expansions, potentially leading to dilution for stockholders if equity is issued, or restrictive covenants if debt is incurred.
• The manufacturing sector, in which acquired companies operate, is cyclical and sensitive to economic conditions, raw material costs, and supply chain disruptions.
• Sales of a substantial number of securities by selling shareholders, or the perception of such sales, could depress the price of common stock and impair future capital raising.
• Issuance of shares upon exercise of derivative securities may cause immediate and substantial dilution to existing stockholders.
• The potential issuances of additional shares under the Purchase Agreement and Pre-Paid Purchases will result in dilution and may negatively impact the market price of common stock.
• Management team will have broad discretion over the use of proceeds from the equity purchase facility, which may not be invested successfully or in ways stockholders agree with.
• The company operates in highly competitive and risky industries, including biopharmaceutical and investment sectors.
• Regulatory bodies might require preclinical bridge studies to pivot EL-22 from Duchenne muscular dystrophy (DMD) to obesity indications, potentially delaying development.
• The ability to proceed with human trials for EL-22 is contingent upon FDA clearing the IND submission.
• The company is exposed to inflation risk, which could impair operating results if labor costs increase significantly.
• The company is subject to market risk from adverse changes in market rates and prices, although it does not engage in speculative transactions.

Future Outlook

The company intends to focus on growing revenue through PMGC Capital's multi-strategy investments, establishing new wholly-owned subsidiaries for biotechnology assets, utilizing clinical validation studies, advancing EL-22 and EL-32 towards IND applications and clinical trials in the U.S., pursuing additional acquisitions, and evaluating potential spin-offs of subsidiaries to unlock shareholder value. The company believes it has sufficient funds for current operations for at least the next 12 months and may seek additional capital to accelerate plans.

Management Comments

• "The Skincare asset divestiture enables us to dedicate more resources and time to advancing our initiatives and assets in larger markets with unmet needs, creating greater growth opportunities for the Company and its shareholders."
• "Our efforts will focus on the clinical development of biotechnology assets through NorthStrive Biosciences Inc. Moreover, this strategic shift positions us to actively explore and execute potential business acquisitions and high-value biotechnology assets, further strengthening our portfolio and driving long-term growth."
• "We believe that EL-22 has the potential to treat obesity in combination with GLP-1 receptor agonists by preserving muscle mass while decreasing fat mass."
• "We believe this urgent unmet medical need could be addressed by both EL-22 and EL-32, that may effectively prevent the loss of muscle mass and increase the fat loss experienced by older patients receiving GLP-1 drugs for the treatment of obesity."
• "We believe our product candidates EL-22 and EL-32 would be the only oral myostatin formulations to date, making Northstrive Bioscience an early mover in the emerging GLP-1 combination space for muscle preservation."
• "We believe that Mr. Bensler’s past experience as our Chief Financial Officer, his familiarity with both the banking and the financial consulting sectors and his having served as an account manager for similarly situated companies makes him a qualified director for our Company."
• "We believe that Mr. Lichti’s past experience as a company founder, director and advisor, and his extensive capital markets and executive experience makes him a qualified director for our Company."

Industry Context

PMGC Holdings is transitioning into a diversified holding company with a strong focus on biotechnology and strategic investments, moving away from physician-dispensed cosmetics. The biotechnology market is experiencing significant growth, projected to reach $1.37 trillion by 2022 and grow at a CAGR of 12.8% from 2023 to 2030, driven by R&D and new therapies. The anti-obesity drug market, particularly GLP-1 receptor agonists, is a high-growth sector expected to reach $100 billion by 2030. PMGC's Northstrive Biosciences is targeting an unmet need within this market: muscle preservation during weight loss, which is a common side effect of GLP-1 drugs. The company's acquisitions in specialty packaging and precision engineering also align with broader advanced manufacturing trends, including demand for high-precision components in aerospace/defense and IT hardware.

Comparison to Industry Standards

• Northstrive Biosciences' EL-22 and EL-32 are positioned as potential first-in-class oral myostatin formulations for muscle preservation in obesity treatment, differentiating them from existing injectable GLP-1 drugs and complementary treatments offered by major players like Novo Nordisk, Eli Lilly, Pfizer, Biohaven, Scholar Rock, and Veru.
• Pacific Sun Packaging differentiates itself from general packaging providers through its specialization in component-level IT hardware packaging, custom engineering capabilities, U.S.-based operations, and established customer base of over 300 commercial customers.
• AGA Precision Systems differentiates itself in the competitive precision machining market through specialized machining of hard and exotic metals to high tolerances, a strong reputation in aerospace, defense, and industrial segments, and existing customer relationships without heavy reliance on marketing expenditures.
• The company's financial performance, with recurring net losses and a going concern warning, is below industry standards for established profitable companies, but may be typical for an emerging growth company heavily investing in R&D and acquisitions.

Management Changes

Corporate Governance

Legal Proceedings

• As of December 31, 2024, the company had an ongoing dispute that arose in the normal course of business. In February 2025, a settlement agreement was reached to resolve all claims, with amounts payable included in accounts payable and accrued liabilities as of December 31, 2024, and paid in full by September 30, 2025.
• As of September 30, 2025, the company had an ongoing dispute that arose in the normal course of business, with mediation discussions ongoing. The likelihood of an unfavorable outcome or the range of potential loss is not yet predictable.

Related Party Transactions

• The company incurred consulting fees and contracted performance bonuses of $504,900 to GB Capital Ltd. (controlled by CEO Graydon Bensler) for the nine months ended September 30, 2025.
• The company incurred consulting fees and contracted performance bonuses of $555,000 to Northstrive Companies Inc. (controlled by Chairman Braeden Lichti) for the nine months ended September 30, 2025.
• GB Capital Ltd. and Northstrive Companies Inc. received 3,036,437 and 3,336,437 shares of Series B Preferred Stock, respectively, as signing bonuses on March 26, 2025, which were accrued as liabilities as of December 31, 2024.
• The company incurred management fees of $13,540 to GB Capital Ltd. and $61,260 to Northstrive Companies Inc. under Secondment Agreements for management services during the nine months ended September 30, 2025.
• As of September 30, 2025, the company had $170,498 in consulting fees due to Graydon Bensler and $315,097 due to companies controlled by Braeden Lichti, which are unsecured, non-interest bearing, and due on demand.
• Amendment No. 3 to consulting agreements for the CEO and Chairman provides for 'Acquisition Awards' (5% to 8% of acquisition value, plus potential 1% bonus) in cash, RSUs, or restricted stock upon consummation of acquisitions.
• The company previously drew $200,000 on an unsecured revolving line of credit from NorthStrive Fund II LP (controlled by Braeden Lichti) at 20% interest, which was repaid in full by December 31, 2024, with $40,000 in interest paid.

Stakeholder Impact

• **Shareholders:** Face significant dilution from the resale of 5,000,000 shares by selling shareholders and potential future issuances under the equity line of credit. Voting power is highly concentrated with management-controlled entities. The 'going concern' warning indicates substantial risk to investment value.
• **Employees:** The company is expanding its executive leadership team with new hires (CFO, President for NorthStrive Biosciences, Communications & Media Lead) but also terminated its CMO and CCO as part of restructuring, indicating potential shifts in operational functions and job security for some roles. Seconded employees from related parties are eligible for group health plans and milestone-driven bonuses.
• **Customers (Pacific Sun Packaging & AGA Precision Systems):** The acquisitions aim to enhance operational efficiencies and expand market penetration, potentially leading to improved product offerings and service reliability. Pacific Sun serves over 300 commercial customers, and AGA serves aerospace, defense, and industrial sectors.
• **Suppliers (Pacific Sun Packaging & AGA Precision Systems):** The company evaluates supplier performance and availability of alternatives, suggesting a focus on supply chain resilience. Two key suppliers represented 28% of cost of goods sold for the nine months ended September 30, 2025.
• **Creditors (Streeterville Capital, LLC):** The company's obligations under the equity line of credit are secured by the assets and equity interests of AGA and Pacific Sun, providing a level of protection for Streeterville Capital, LLC.

Next Steps

• File an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to evaluate EL-22 in combination with GLP-1 receptor agonists.
• Initiate clinical trials in the U.S. for EL-22, contingent upon FDA clearance of the IND submission.
• Continue clinical development of EL-32, a preclinical probiotic for muscle preservation.
• Pursue additional acquisitions of operating companies and biotechnology assets to expand and diversify the portfolio.
• Evaluate potential spin-offs of wholly-owned subsidiaries to unlock shareholder value.
• Grow revenue by achieving successful returns on capital through PMGC Capital's multi-strategy investment vehicle.
• Utilize clinical validation studies to strengthen the commercial potential and scientific credibility of portfolio companies' technologies.
• Formalize business development and marketing efforts for AGA Precision Systems to reach new customers.
• Invest in expanded production capacity and efficiency improvements for AGA Precision Systems.
• Monitor the IPR&D asset (License #2) for impairment indicators consistent with U.S. GAAP.
• Complete the evaluation of purchase price allocation and fair value of identifiable assets acquired and liabilities assumed for the Indarg Engineering, Inc. acquisition.

Key Dates

Recommendation

The company's financial health is precarious, evidenced by recurring net losses, increasing cash burn from operations, and an explicit 'going concern' warning from its auditors. While recent capital raises provide some liquidity, they come at the cost of significant shareholder dilution. The high concentration of voting control with management-controlled entities, coupled with substantial related-party transactions, raises red flags regarding corporate governance and potential conflicts of interest. The strategic shift and acquisitions are positive in theory, but the immediate financial performance and the inherent risks of operating in highly competitive and capital-intensive industries (biotechnology, manufacturing) without a clear path to profitability make this a high-risk investment. The potential for further dilution from the resale of 5 million shares and future equity line draws, combined with the current stock price of $5.26, suggests that the downside risk outweighs the speculative upside. A seasoned investor would likely view these factors as strong reasons to exit or avoid the stock.

Keywords

Biotechnology, SEC Filing, S-1/A, Equity Line of Credit, Acquisitions, Biopharmaceutical, Obesity Treatment, GLP-1 Agonists, Muscle Preservation, Probiotic, CNC Machining, Specialty Packaging, Financial Reporting, Going Concern, Dilution, Related Party Transactions, Corporate Governance, Nasdaq, Reverse Stock Split, Warrants